By Sabine Ruehle, Pierre Omnes, Kathryn Parsley, Gabriel Bohl, Myra Widjojoatmodjo, Janneke Westra-de Vlieger, Jayne Hunt,
supportive members of the TOPRA Biotech and Clinical Trial SPIN groups2023-05-18T12:58:00
The EU CTR replaced the EU CTD on 31 January 2022, which impacts investigational medicinal products that fall under genetically modified organisms (GMO-IMPs). This article discusses the specificities of the new CTR process for GMO-IMPs and updates on the GMO application processes in light of these changes.
Join now to get access to:
Not sure yet? Read one of our free editorials to see what you’re missing out on!
The peer-reviewed journal, published 11 times per year and available free to TOPRA members.
The Organisation for Professionals in Regulatory Affairs
TOPRA Publishing, 6th Floor, 3 Harbour Exchange, South Quay, London E14 9GE, UK
Tel: +44 (0) 20 7510 2560
Blvd du Souverain 280, 1160 Brussels, Belgium
Tel: +32 (0) 2 808 72 70